{"id":148978,"date":"2026-10-23T17:23:39","date_gmt":"2026-10-23T17:23:39","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/148978\/"},"modified":"2026-10-23T17:23:39","modified_gmt":"2026-10-23T17:23:39","slug":"novartis-ms-treatment-cuts-rates-of-relapse-in-pivotal-trials","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/148978\/","title":{"rendered":"Novartis MS treatment cuts rates of relapse in pivotal trials"},"content":{"rendered":"<p class=\"author-bio\">Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.<\/p>\n<p class=\"wp-block-paragraph\">A multiple sclerosis treatment from Novartis cut by a third the rates of relapses that people with the condition have compared to a standard treatment, data presented Friday show. While that efficacy doesn\u2019t match the performance of a rival drug from Roche, Novartis\u2019 treatment has a cleaner safety profile that could give it a shot at being competitive in the market.<\/p>\n<p class=\"wp-block-paragraph\">In two Phase 3 studies in the relapsing form of MS, the Novartis drug, called remibrutinib, reduced the so-called annualized relapse rate by 35.2% and 31.2% when tested against Sanofi\u2019s approved drug Aubagio. That translates into about one relapse every 13 years, Heinz Wiendl, a neurologist at the University of Freiburg, said while presenting the data from the REMODEL-1 and -2 studies at an MS conference in Toronto.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">In its own pivotal studies, Roche\u2019s drug fenebrutinib <a href=\"https:\/\/www.statnews.com\/2026\/04\/21\/roche-multiple-scleroris-efficacy-safety\/\" rel=\"nofollow noopener\" target=\"_blank\">cut the relapse rate<\/a> by more than 50% versus Aubagio.\u00a0<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/10\/1792776219_428_stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially&hellip;\n","protected":false},"author":2,"featured_media":148979,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[336,6904,14354,206,339],"class_list":["post-148978","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-biotechnology","tag-chronic-disease","tag-esmo","tag-novartis","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117491387942360552","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/148978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=148978"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/148978\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/148979"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=148978"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=148978"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=148978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}